Use of MG series monoclonal antibodies in the diagnosis and experimental targeting therapy of gastric cancer.
In order to facilitate early diagnosis and improve the treatment of gastric cancer, 12 murine hybridoma cell lines capable of producing monoclonal antibodies (mAb) against gastric cancer were established. These monoclonal antibodies were used in histopathological diagnosis, cytological and serological diagnosis, and radioimmunoimaging (RII). Also, immunoconjugates and immunoliposomes were produced by linking these antibodies with various anticancer agents. In vitro and in vivo studies in mice were carried out to investigate the possible uses of these antibodies in experimental targeting therapy of gastric cancer. This paper presents a review of these studies.
Zhang
X
X
Xijing Hospital, Xi'an.
Li
S
S
Fan
D
D
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000175:diagnosis; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000922:Immunotoxins